Kirtland Hills Capital Management LLC Acquires Shares of 3,191 Stryker Corporation $SYK

Kirtland Hills Capital Management LLC acquired a new stake in shares of Stryker Corporation (NYSE:SYK) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 3,191 shares of the medical technology company’s stock, valued at approximately $1,005,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Varma Mutual Pension Insurance Co lifted its stake in Stryker by 10.5% in the fourth quarter. Varma Mutual Pension Insurance Co now owns 53,610 shares of the medical technology company’s stock worth $18,842,000 after acquiring an additional 5,100 shares during the period. QRG Capital Management Inc. increased its position in Stryker by 7.4% during the 4th quarter. QRG Capital Management Inc. now owns 60,548 shares of the medical technology company’s stock valued at $21,281,000 after purchasing an additional 4,186 shares during the period. Swedbank AB raised its holdings in Stryker by 6.6% in the 4th quarter. Swedbank AB now owns 129,027 shares of the medical technology company’s stock worth $45,349,000 after purchasing an additional 7,934 shares in the last quarter. Crossmark Global Holdings Inc. raised its stake in Stryker by 31.1% in the fourth quarter. Crossmark Global Holdings Inc. now owns 26,820 shares of the medical technology company’s stock worth $9,426,000 after buying an additional 6,367 shares in the last quarter. Finally, Royal Bank of Canada lifted its holdings in Stryker by 6.5% in the first quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company’s stock worth $1,075,552,000 after buying an additional 199,863 shares during the period. Institutional investors own 77.09% of the company’s stock.

Trending Headlines about Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker’s long-term outlook remains supported by steady demand for its medical technologies, continued Mako robotics growth and improving margins. The company’s latest quarter exceeded expectations, with earnings of $3.69 per share on $6.59 billion in revenue, while revenue increased 9.4% year over year. Here’s Why You Should Hold Stryker Stock in Your Portfolio for Now
• Positive Sentiment: Wall Street remains broadly constructive: consensus calls for a “Moderate Buy” rating, with 18 analysts recommending Buy or Strong Buy versus six Holds. The average target of $386.28 implies meaningful upside from recent trading levels, although several firms have lowered their individual targets. Are Wall Street Analysts Predicting Stryker Stock Will Climb or Sink?
• Neutral Sentiment: Stryker maintained its fiscal 2026 earnings guidance of $14.95 to $15.10 per share and recently declared a quarterly dividend of $0.88, equivalent to a 1.1% annual yield. Institutional ownership remains high at approximately 77%, indicating continued support from large investors.
• Negative Sentiment: Director Ronda Stryker sold a combined 350,000 shares for approximately $117.8 million across August 18–19. Although she still owns more than 2.25 million shares, the transactions reduced her direct ownership and may raise caution among investors. Stryker Director Sells Shares
• Negative Sentiment: Recent commentary highlights execution risks, including cyber and supply-chain disruptions, while analysts have trimmed targets after an imperfect second quarter. BTIG reduced its target to $358 and JPMorgan lowered its target to $350, contributing to near-term pressure despite their Buy and Overweight ratings. Stryker Sell-Off Analysis

Analysts Set New Price Targets

A number of research firms have recently commented on SYK. Needham & Company LLC lowered their target price on Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a research note on Friday, May 1st. JPMorgan Chase & Co. dropped their target price on shares of Stryker from $400.00 to $350.00 and set an “overweight” rating on the stock in a report on Friday, July 31st. Wells Fargo & Company reduced their target price on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a research report on Friday, May 1st. Sanford C. Bernstein set a $410.00 price target on shares of Stryker in a research report on Friday, May 1st. Finally, Wall Street Zen upgraded shares of Stryker from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $386.28.

Stryker Trading Up 0.7%

NYSE:SYK opened at $329.86 on Friday. The company has a market cap of $126.52 billion, a PE ratio of 34.18, a price-to-earnings-growth ratio of 2.10 and a beta of 0.76. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. The company has a 50 day simple moving average of $326.99 and a two-hundred day simple moving average of $332.64. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $396.86.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating the consensus estimate of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. The business’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Research analysts forecast that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a $0.88 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker’s dividend payout ratio (DPR) is presently 36.48%.

Insider Transactions at Stryker

In other news, insider Debra King sold 826 shares of the business’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the sale, the insider owned 6,210 shares of the company’s stock, valued at $2,088,423. The trade was a 11.74% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the sale, the director owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. This trade represents a 13.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 665,370 shares of company stock worth $216,238,501 in the last 90 days. 4.60% of the stock is currently owned by insiders.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.